As extreme pricing is becoming more the norm, insurers and prescription-benefit managers are pushing for pay-for-performance deals, where the patient would pay according to the benefit they receive from the drug. Drug companies, however, are countering with price models of their own. Read more here. (Source: Peter Loftus, The Wall Street Journal, 5/26/15)
You are here: / / Should Pharmaceutical Pricing Be Linked to Performance?